Half-year report · HY
9273.TEDINET S100XK39
Period2025-07-01 → 2025-12-31
Filed2026-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.7bn | 2025-07-01 → 2025-12-31 | Cons. | Net sales |
| Revenue | ¥23.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Operating income | ¥3.2bn | 2025-07-01 → 2025-12-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2025-07-01 → 2025-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2025-07-01 → 2025-12-31 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Total assets | ¥36.5bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥36.1bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2025-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.0bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥29.6bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥28.1bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.2bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.9bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.0bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.7bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥360m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥829m | 2025-07-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥939m | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥49.53 | 2025-07-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.38 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 80.9% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.9% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2025-12-31 | −¥649m |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2025-12-31 | ¥46m |
| Drug Substance Sales Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥8.5bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥7.8bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| Drug Substance Sales Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2025-07-01 → 2025-12-31 | ¥4.8bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2025-07-01 → 2025-12-31 | ¥1.3bn |
| —segment total | revenue | 2025-07-01 → 2025-12-31 | ¥13.3bn |
| —segment total | revenue external | 2025-07-01 → 2025-12-31 | ¥12.7bn |
| —segment total | revenue intersegment | 2025-07-01 → 2025-12-31 | ¥649m |
| —segment total | segment profit | 2025-07-01 → 2025-12-31 | ¥3.1bn |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 495
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 603822000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -603822000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 8012272000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 4851001000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 12863273000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -603822000 | JPY |
| Net sales | Prior1InterimDuration | 12259451000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 1596054000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 1385974000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 2982029000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | 81448000 | JPY |
| Operating income | Prior1InterimDuration | 3063478000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 7818352000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 4836067000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 12654420000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 12654420000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 649421000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 649421000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -649421000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 8467774000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 4836067000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 13303842000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -649421000 | JPY |
| Net sales | InterimDuration | 12654420000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 1783338000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 1339314000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 3122653000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | 46401000 | JPY |
| Operating income | InterimDuration | 3169055000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-02-10 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第12期中（自 2025年７月１日 至 2025年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)コーア商事ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | KOA SHOJI HOLDINGS CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 首藤 利幸 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)神奈川県横浜市港北区日吉七丁目13番15号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 045-560-6607 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務取締役 小松 美代子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)神奈川県横浜市港北区日吉七丁目13番15号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 045-560-6607 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務取締役 小松 美代子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E34071 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |